MCM
CYTK icon

Matarin Capital Management’s Cytokinetics CYTK Stock Holding History

Matarin Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-69,882
Closed -$1.01M – 295
2017
Q3 		$1.01M Hold
69,882
– – 0.09% 195
2017
Q2 		$846K Buy
69,882
+49,593
+244% +$689K 0.08% 192
2017
Q1 		$261K Buy
+20,289
New +$237K 0.03% 256
2016
Q3 		– Sell
-44,720
Closed -$424K – 236
2016
Q2 		$424K Sell
44,720
-226,810
-84% -$1.86M 0.06% 203
2016
Q1 		$1.91M Buy
271,530
+31,367
+13% +$229K 0.27% 138
2015
Q4 		$2.51M Buy
240,163
+79,396
+49% +$779K 0.38% 116
2015
Q3 		$1.08M Buy
+160,767
New +$1.1M 0.22% 135

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Matarin Capital Management's CYTK Position: Q4 2017 in Review

Matarin Capital Management sold out of Cytokinetics (CYTK) in Q4 2017, closing a stake of 69,882 shares — an estimated $1.01M sold.

Matarin Capital Management first reported a position in CYTK in Q3 2015 and held it in 7 quarters. The position peaked at $2.51M in Q4 2015. 134 funds tracked by Wall St. Rank hold CYTK as of Q4 2017.

  • Matarin Capital Management reported no remaining Cytokinetics position as of Q4 2017 after selling out during the quarter.
  • Matarin Capital Management sold 69,882 Cytokinetics shares in Q4 2017, an estimated $1.01M.
  • Matarin Capital Management first reported a position in Cytokinetics in Q3 2015 and held it in 7 quarters.
  • Matarin Capital Management's Cytokinetics position peaked at $2.51M in Q4 2015.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2017.

Based on Matarin Capital Management's 13F filing for Q4 2017, filed 8 Feb 2018.